
Liquidity, historical trends, and peer comparisons.
According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.71. This represents a change of 81.57% compared to the average of 5.35 of the last 4 quarters.
The mean historical Current Ratio of ALX Oncology Holdings Inc. over the last ten years is 15.73. The current 9.71 Current Ratio has changed -38.27% with respect to the historical average. Over the past ten years (40 quarters), ALXO's Current Ratio was at its highest in in the December 2020 quarter at 70.28. The Current Ratio was at its lowest in in the March 2019 quarter at 0.
Average
15.73
Median
6.36
Minimum
1.97
Maximum
70.28
Discovering the peaks and valleys of ALX Oncology Holdings Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.47%
Maximum Annual Current Ratio = 70.28
Minimum Annual Increase = -71.55%
Minimum Annual Current Ratio = 1.97
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 2.07 | -71.55% |
| 2024 | 7.26 | 38.58% |
| 2023 | 5.24 | -45.22% |
| 2022 | 9.57 | -60.13% |
| 2021 | 24.00 | -65.85% |
| 2020 | 70.28 | 3.47% |
| 2019 | 1.97 | -63.89% |
The current Current Ratio of ALX Oncology Holdings Inc. (ALXO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
4.86
5-year avg
9.63
10-year avg
15.73
ALX Oncology Holdings Inc.’s Current Ratio is greater than Annexon, Inc. (5.53), less than Bicycle Therapeutics plc (12.09), greater than Monte Rosa Therapeutics, Inc. (9.52), less than Kymera Therapeutics, Inc. (11.13), greater than Nkarta, Inc. (7.98), greater than Stoke Therapeutics, Inc. (7.24), greater than Tenaya Therapeutics, Inc. (4.52),
| Company | Current Ratio | Market cap |
|---|---|---|
| 5.53 | $645.54M | |
| 12.09 | $253.37M | |
| 9.52 | $906.88M | |
| 11.13 | $10.89B | |
| 7.98 | $108.87M | |
| 7.24 | $1.71B | |
| 4.52 | $82.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is ALX Oncology Holdings Inc.'s Current Ratio?
How is the Current Ratio calculated for ALX Oncology Holdings Inc. (ALXO)?
What is the highest Current Ratio for ALX Oncology Holdings Inc. (ALXO)?
What is the 3-year average Current Ratio for ALX Oncology Holdings Inc. (ALXO)?
What is the 5-year average Current Ratio for ALX Oncology Holdings Inc. (ALXO)?
How does the current Current Ratio for ALX Oncology Holdings Inc. (ALXO) compare to its historical average?